Radiological or Nuclear Medical Countermeasure Product Development Support (PDS)
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The National Institute of Allergy and Infectious Diseases (NIAID) is conducting a Small Business Sources Sought to identify qualified small businesses for Radiological or Nuclear Medical Countermeasure Product Development Support (PDS). This is market research to inform a potential 7-year Indefinite Delivery, Indefinite Quantity (IDIQ) contract. Capability Statements are due by February 17, 2026.
Scope of Work
This effort aims to develop clinical tools and strategies for mitigating and treating multi-organ injuries and persistent inflammation following acute radiation exposure. The contractor will provide facilities, expertise, and capabilities for the development of radiation/nuclear medical countermeasures (MCMs) for Acute Radiation Syndrome (ARS) and delayed effects of acute radiation exposure (DEARE). The work, initiated by NIAID, will not involve basic research but will focus on developing, testing, and preparing government-selected products for FDA approval. Key areas include:
- Animal models of radiation injury and MCM testing.
- IND-enabling product development support.
- Sample collection for radiation injury biomarkers.
- Animal safety studies (pharmacokinetic, pharmacodynamic).
- Manufacturing and formulation processes, quality assurance.
- Phase I Clinical Studies. The anticipated IDIQ will cover five task areas: Administrative and Technical Support; Animal Model and New Approach Methodologies (NAMs) Development and Efficacy Testing; Non-Clinical Studies for IND/NDA/BLA Submissions; Chemistry, Manufacturing, and Control (CMC) Support; and Phase I Clinical Studies and Support.
Contract & Timeline
- Type: Sources Sought (market research for an anticipated IDIQ)
- Anticipated Contract Type: Single Indefinite Delivery, Indefinite Quantity (IDIQ)
- Anticipated Duration: 7 years (July 1, 2027, to June 30, 2034)
- Set-Aside: Small Business
- Response Due: February 17, 2026, at 3:00 PM E.S.T.
- Published: January 30, 2026
Evaluation
Responses will assist the Government in determining the appropriate acquisition method, including potential set-asides. Interested small businesses must submit tailored Capability Statements (max 10 pages per Task Area, excluding resumes) demonstrating qualifications, expertise, and experience for each of the five task areas. Required information includes UEI, company details, GSA Schedules/GWACs, accounting system approval, and SAM-validated company type.
Additional Notes
This is NOT a solicitation for proposals. The Government is not obligated to award a contract or pay for information provided. No proprietary, classified, or sensitive information should be included.